SYNthesis med chem is a global provider of small molecule drug discovery services. Our ‘Best of Both Worlds’ approach uniquely combines world class, industry-proven medicinal chemistry expertise with innovative, flexible, reliable and cost-effective synthetic chemistry resources.

Together with our parent company, Viva Biotech , we work across disciplines including protein sciences and structural biology, biological target validation and hit finding, biophysical screening, biofunctional assays, DMPK and pharmacology, to progress programs from initial idea, hit finding, into hit-to-lead, through lead optimisation and to clinical candidate nomination.

Whether we work as a part of an integrated Discovery team or work to deliver a bespoke library of targets, Medicinal Chemistry is at the heart of all we do and is reflected in contributions to a wide range of modalities such as traditional small molecules, molecular glues and PROTACs, peptides, Antibody-drug-conjugates (ADCs), peptide-drug-conjugates (PDCs).

Why work with us

Viva and its subsidiary, SYNthesis med chem are different from most of other CROs （customer research organizations) as we have:

●World-leading protein production & structural biology (X-ray, Cryo-EM) capacities: we deliver more than 95,000 structures from about 850 proteins;

●Strong affinity screening capabilities (ASMS, SPR and V-DEL) enabled by fragment, GPCR, covalent, & diversity libraries

●Extensive medicinal chemistry track record, from Hit ID to H2L to LO to candidate nomination, across modalities including small molecule drugs, PROTACs & molecule glues, peptides, and ADCs

●AI-enabled integrated drug discovery and development services

●“Best of both worlds” approach with excellent communications and high quality “integrated services”